乳腺分泌型癌的研究进展  

Research progress of secretory breast carcinoma

作　　者：宋雨欣 徐峥 徐迪[1] 张建[1] 李蕾 王丹丹[1] 肖璇[1] 唐金海[1] SONG Yuxin;XU Zheng;XU Di;ZHANG Jian;LI Lei;WANG Dandan;XIAO Xuan;TANG Jinhai(Department of General Surgery, the First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China)

机构地区：[1]南京医科大学第一附属医院普外科,江苏南京210029

出　　处：《中国肿瘤外科杂志》2022年第3期252-256,共5页Chinese Journal of Surgical Oncology

基　　金：国家自然科学基金青年项目(81902987)。

摘　　要：乳腺分泌型癌是一类发病率约0.015%的罕见乳腺恶性肿瘤,分布于男女的各年龄段。临床常表现为单发、无痛的乳晕下或乳房外上象限肿物,症状持续时间长。病理特征为组织学可见肿瘤细胞内外大量嗜酸性分泌物,原位免疫荧光检查可见典型ETV6-NTRK3融合基因。目前该病的治疗方法与非特殊类型乳腺癌相似,以初期手术治疗为主,辅以放化疗等全身治疗,尚缺乏针对性。大部分乳腺分泌型癌案例的恶性程度较低,疾病进展缓慢,预后良好,而极少部分案例呈现出较强的侵袭性病程并最终引起个体死亡。该文旨在通过回顾既往案例总结乳腺分泌型癌的临床病理特点、分子遗传致病机制和个体化治疗策略,并重点讨论部分强侵袭性案例,探究与不良预后相关的危险因素。Secretory breast carcinoma(SBC)is a rare and unique breast tumor accounting for about 0.015%of all breast cancer,which covers all ages of males and females.It is characterized by solitary,painless of subareolar or upper outer quadrant breast mass with a long duration.Histology showed many eosinophilic secretory materials inside and outside tumor cells.A typical ETV6-NTRK3 fusion gene can be observed by fluorescence in situ hybridization.Up to date,the therapeutic strategies of SBC were similar to that of common breast cancer,which is primary surgical treatment accompanied with radiotherapy and chemotherapy.The majority of SBC presents indolent clinical behavior,low malignancy,and well prognosis.While a minority exhibits aggressive disease progression and finally causes fatal outcomes.The purpose of this paper was to summarize the clinicopathological characteristics,pathogenic molecular basis and individualized treatment strategies of SBC by reviewing previous cases.

关 键 词：乳腺分泌型癌 病理 免疫组化 手术 治疗 

分 类 号：R737.9[医药卫生—肿瘤]